Pịa ebe a ma ọ bụrụ na nke a bụ ntọhapụ mgbasa ozi gị!

Ọgwụ mgbochi COVID-19 nke ọgbọ ọhụrụ

Jiangsu Recbio Technology Co., Ltd. ("Recbio"), ụlọ ọrụ biopharmaceutical na-elekwasị anya na nyocha, mmepe na ịzụ ahịa nke ọgwụ mgbochi ọhụrụ nke nwere ike ịgwọ ọrịa ndị jupụtara na ibu dị arọ, taa kwupụtara nsonaazụ mmalite dị mma sitere na mmadụ mbụ (FIH). ) nnwale nke ReCOV, ọgbọ ọhụrụ, ọgwụ mgbochi COVID-19 mejupụtara akụkụ abụọ. N'ozuzu, data mbido gosipụtara na ReCOV kwadoro nke ọma ma gosipụta profaịlụ nchekwa dị mma. 20μg ReCOV butere ọkwa dị elu nke mgbochi SARS-CoV-2 na-egbochi ọgwụ mgbochi, yana opekata mpe nha anya karịa data ebipụtara na ọgwụ mgbochi mRNA, na-ebu amụma ikike ReCOV na-egbochi ọrịa SARS-COV-2 butere.

Print Friendly, PDF & Email

         

"A na-agba anyị ume site na nchekwa mbụ na profaịlụ immunogenicity nke ReCOV na ule FIH a," Dr. Liu Yong, Onye isi oche na Onye isi njikwa kwuru. "Ọgwụ mgbochi mgbochi ka bụ ụzọ kachasị dị irè iji gbochie ọrịa SARS-CoV-2 na ịchịkwa ọrịa na-efe efe zuru ụwa ọnụ. Anyị na-atụ anya ịnye ọgbọ ọzọ nke ọgwụ mgbochi COVID-19 nwere ike dị na nchekwa, ịdị mma na nnweta, ma ga-ebuli ReCOV n'ime ọmụmụ ụlọ ọgwụ buru ibu n'oge na-adịghị anya iji nyochaa ịdị mma na nchekwa ya. "

Ọnwụnwa FIH a na-aga n'ihu bụ usoro nyocha, kpuru ìsì abụọ, ebe a na-achịkwa ebebo iji nyochaa nchekwa, reactogenicity, na immunogenicity nke 2 na-arịgo doses nke ReCOV, mgbe a na-enye ya dị ka injections intramuscular 2 (ya na ụbọchị 21 dị iche) na isiokwu ahụike. Taa Recbio kọrọ data nchekwa ekpuchighị ekpuchi, mmeghachi omume na immunogenicity maka ndị otu 1 (ndị okenye na-eto eto/ReCOV 20μg).

Ndị otu a debanyere ndị sonyere 25 bụ ndị dị afọ 18 ruo 55. N'ime nnwale ahụ, agbanwere SARS-Cov-2-neutralizing antibody geometric mean titers (GMTs) ka ọ bụrụ ngalaba WHO/NIBSC nke IU/mL maka ntụnyere nke iwepu ihe mgbochi mgbochi na nke ọgwụ mgbochi ndị ọzọ a na-ejikarị. Recbio nwetara GMT nke 1643.2 IU/mL maka iwepu ọgwụ mgbochi na ụbọchị iri na anọ ka usoro ọgwụgwọ abụọ nke ReCOV gasịrị, yana ọnụọgụ seropositive (SPR) na ọnụego seroconversion (SCR) dị ka 14%, na-atụ aro ịdị mma nke ReCOV na igbochi SARS-COV-100. butere ọrịa. Emere ọgwụ mgbochi SARS-CoV-2 site na ụlọ nyocha etiti nke ọmụmụ (2Biolabs). Dabere na ọmụmụ akwụkwọ mbipụta na nso nso a, GMT nke SARSCoV-360 mgbochi mgbochi mgbochi bụ 1 IU/mL na 2 IU/ml ụbọchị 1404.16 ka usoro ọgwụgwọ abụọ gachara maka ọgwụ mgbochi Moderna na BioNTech/Pfizer mRNA, n'otu n'otu.

N'ụzọ doro anya, dabere na plasma mmadụ gbakọtara site na ndị ọrịa na-ahụ anya, ọkọlọtọ mba ụwa nke WHO (gụnyere 20/136, nke National Institute for Biological Standards and Control [NIBSC] nyere) ka a na-ejikarị mee ihe iji dozie usoro nyocha dị iche iche.

Ka ọ dị ugbu a, data immunogenicity cellular gosipụtara na ReCOV nwere ike iweta nzaghachi antigen-kpọmkwem CD4 + T cell na ndị toro eto, na-egosipụta na mmepụta IFN-γ na IL-2, omume doro anya na Th1 phenotype hụrụ na ọkwa kachasị elu nke cytokines Th1 achọpụtara na Ụbọchị 36 (ụbọchị iri na anọ mgbe ịgba ọgwụ mgbochi nke abụọ gasịrị).

A na-anabatakarị ReCOV nke ọma site na ezigbo nchekwa yana profaịlụ nnabata. Ọtụtụ n'ime ihe ọjọọ dị obere n'ịdị njọ. Enweghị SAE ma ọ bụ TEAE nke na-eduga n'ịkwụsị n'oge, enweghị akara dị oke mkpa dị mkpa / nsonaazụ ụlọ nyocha nwere mkpa ụlọ ọgwụ.

Recbio mepụtara nyiwe teknụzụ na-egbutu ọnụ atọ maka mmepe adjuvant ọhụrụ, injinịa protein na nyocha ọgwụ mgbochi. N'ịkwado site na nyiwe ndị a, Recbio na-aga n'ihu na-achọpụta ma na-emepụta ọnụ ọgụgụ zuru ezu nke ndị na-achọ ọgwụ mgbochi ọhụrụ, dị ka ọgbọ na-esote HPV, shingles na flu.

Print Friendly, PDF & Email

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ bụ Linda Hohnholz.

Ahapụ a Comment

1 Comment

  • Linda mma,
    Ị gaghị eche n'echiche ole akụkọ gị na-enye ndị dị ka m na obodo m olileanya, nke dị na nsọtụ ọzọ nke ụwa. Anyị tụfuru olile anya kpamkpam ma anyị ga-esi n'ọwara pụta gbasara ọrịa Covid a. Linda maam, ị bụ onye ozi nke Chineke. Chineke na-echekwa gị, ezi na ụlọ gị na obodo gị kwa.